ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SYNC Syncona Limited

121.40
-0.60 (-0.49%)
Last Updated: 12:01:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60 -0.49% 121.40 121.20 121.80 122.60 121.20 121.20 228,743 12:01:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.45 809.41M

Syncona Limited 2019 Dividend Scrip Reference Price (8597D)

28/06/2019 12:33pm

UK Regulatory


Syncona (LSE:SYNC)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Syncona Charts.

TIDMSYNC

RNS Number : 8597D

Syncona Limited

28 June 2019

Syncona Limited

2019 Dividend Scrip Reference Price

28 June 2019

Syncona Ltd announces that the scrip reference price for its 2019 dividend will be GBP2.281. This is the higher of (i) the prevailing average of the middle market quotations of its ordinary shares derived from the Daily Official List of the London Stock Exchange for the ex-dividend date, 20 June 2019, and the four subsequent dealing days and (ii) the net asset value per ordinary share as at 31 March 2019.

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel : +44 (0) 20 3981 7940

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DIVUWOARKUANUAR

(END) Dow Jones Newswires

June 28, 2019 07:33 ET (11:33 GMT)

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock